OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 02:24:33 2024-06-27 EDT | ||
| 31.28 EUR | -0.38% |
|
| Current month | +7.09% | ||
| 1 month | +6.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 31.28 | -0.38% |
| 24-06-26 | 31.4 | +0.58% |
| 24-06-25 | 31.22 | -0.51% |
| 24-06-24 | 31.38 | +0.87% |
| 24-06-21 | 31.11 | +0.10% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 02:24 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF8RXA |
| ISIN | DE000SF8RXA1 |
| Date issued | 2021-10-05 |
| Strike | 138.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 32.28 € |
|---|---|
| Lowest since issue | 5.56 € |
| Spread | 0.34 € |
| Spread % | 1.08% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
